Reaction
Graft Versus Host Disease In Lung reporting signals
As of the last recalculation, Graft Versus Host Disease In Lung appears in 469 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 113.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Busulfan | 37 | 113.2 | 113.5 |
| Imatinib | 33 | 89.2 | 89.4 |
| Tacrolimus Ointment 0.1% | 148 | 76.6 | 76.7 |
| Tacrolimus Extended-Release Capsules | 148 | 76.4 | 76.5 |
| Mycophenolate Mofetil Hydrochloride | 151 | 72.2 | 72.2 |
| Posaconazole | 25 | 72.1 | 72.2 |
| Ganciclovir | 16 | 71.8 | 71.9 |
| Mycophenolate Mofetil | 150 | 71.6 | 71.7 |
| Tacrolimus | 164 | 70.9 | 71.0 |
| Ganciclovir Sodium | 16 | 69.4 | 69.5 |
| Thiotepa | 14 | 67.0 | 67.1 |
| Posaconazole Delayed-Release | 16 | 66.9 | 67.0 |
| Fludarabine Phosphate | 51 | 64.5 | 64.5 |
| Azacitidine For | 21 | 53.6 | 53.7 |
| Alemtuzumab | 22 | 52.9 | 53.0 |
| Mycophenilic Acid | 23 | 51.7 | 51.8 |
| Voriconazole Injection | 23 | 49.4 | 49.4 |
| Blinatumomab | 11 | 47.9 | 47.9 |
| Ruxolitinib | 63 | 44.9 | 45.0 |
| Micafungin Sodium | 8 | 42.6 | 42.6 |
| Atovaquone | 7 | 39.2 | 39.2 |
| Melphalan | 19 | 38.6 | 38.6 |
| Voriconazole | 25 | 38.5 | 38.6 |
| Sirolimus | 11 | 37.1 | 37.1 |
| Mycophenolic Acid | 25 | 36.6 | 36.6 |
| Melphalan Hydrochloride | 19 | 35.0 | 35.0 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 33.4 | 33.4 |
| Azacitidine | 21 | 32.8 | 32.9 |
| Cladribine | 6 | 28.1 | 28.1 |
| Sorafenib | 11 | 24.0 | 24.1 |